121 lines
80 KiB
Text
121 lines
80 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK599526">
|
|
<meta name="ncbi_domain" content="statpearls">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK599526/?report=reader">
|
|
<meta name="ncbi_pagename" content="Sclerotherapy - StatPearls - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Sclerotherapy - StatPearls - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="StatPearls [Internet]">
|
|
<meta name="citation_title" content="Sclerotherapy">
|
|
<meta name="citation_publisher" content="StatPearls Publishing">
|
|
<meta name="citation_date" content="2024/01/11">
|
|
<meta name="citation_author" content="Amanda Beneat">
|
|
<meta name="citation_author" content="Alisha Oropallo">
|
|
<meta name="citation_pmid" content="38261698">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK599526/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Sclerotherapy">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="StatPearls Publishing">
|
|
<meta name="DC.Contributor" content="Amanda Beneat">
|
|
<meta name="DC.Contributor" content="Alisha Oropallo">
|
|
<meta name="DC.Date" content="2024/01/11">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK599526/">
|
|
<meta name="description" content="Sclerotherapy is a group of techniques characterized by the injection of an irritating substance into a blood vessel to damage the vessel endothelium, induce inflammation with subsequent endofibrosis, and destroy the vessel.[1][2][3] The irritating substances are termed sclerosing agents and include osmotic agents such as glycerin and hypertonic saline, detergents like polidocanol and sodium tetradecyl sulfate (STS), and iodinated substances.[2][4] Sclerotherapy is most commonly a primary or adjunctive therapy for cosmetically distressing or symptomatic venous varicosities of the lower extremities, but it also may be employed when treating certain hemorrhoids.[5] Sclerotherapy remains the gold standard therapeutic intervention for lower extremity superficial varicose veins, reticular veins, and telangiectasia. ">
|
|
<meta name="og:title" content="Sclerotherapy">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Sclerotherapy is a group of techniques characterized by the injection of an irritating substance into a blood vessel to damage the vessel endothelium, induce inflammation with subsequent endofibrosis, and destroy the vessel.[1][2][3] The irritating substances are termed sclerosing agents and include osmotic agents such as glycerin and hypertonic saline, detergents like polidocanol and sodium tetradecyl sulfate (STS), and iodinated substances.[2][4] Sclerotherapy is most commonly a primary or adjunctive therapy for cosmetically distressing or symptomatic venous varicosities of the lower extremities, but it also may be employed when treating certain hemorrhoids.[5] Sclerotherapy remains the gold standard therapeutic intervention for lower extremity superficial varicose veins, reticular veins, and telangiectasia. ">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK599526/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/statpearls/article-145193/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK599526/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8DA8B77C9135A10000000000C700A1.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK599526/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"></div><div class="body"><div class="t">Sclerotherapy</div><div class="j">StatPearls [Internet]</div></div><div class="tail"></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK599526/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK599526/&text=Sclerotherapy"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/statpearls/?report=reader">Title Information</a><a href="/books/n/statpearls/toc/?report=reader">Table of Contents Page</a><a href="#_NBK599526_">Sclerotherapy</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK599526/?report=classic">Switch to classic view</a><a href="/books/NBK599526/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK599526%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8DA8B77C9135A10000000000C700A1.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK599526_"><span class="title" itemprop="name">Sclerotherapy</span></h1><p class="contribs">Beneat A, Oropallo A.</p><p class="fm-aai"><a href="#_NBK599526_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="article-145193.s1"><h2 id="_article-145193_s1_">Continuing Education Activity</h2><p>Injection sclerotherapy is a minimally invasive primary or adjunctive procedure that is a cornerstone in managing venous varicosities, including varicose, reticular, and spider veins, telangiectasias, and some hemorrhoids. Injection sclerotherapy induces vascular fibrosis, improves cosmesis, relieves venous insufficiency symptoms, and improves overall vascular health. Sclerotherapy offers substantial therapeutic benefits with a low complication rate and can frequently be performed in an office-based setting. Various sclerosants are available, each with their indication and best practice profile. Sclerotherapy may be performed with or without ultrasound guidance. This activity reviews the pathophysiology and classification of venous varicosities, the indications, contraindications, and complications of injection sclerotherapy, and the latest advancements in sclerosing agents, procedural techniques, and best practices. The activity also highlights the role of the interprofessional, multidisciplinary team in engaging in shared decision-making with patients, ensuring individualized treatment plans aligned with patient preferences and expectations, and improving outcomes for patients undergoing injection sclerotherapy for the treatment of venous varicosities.</p><p>
|
|
<b>Objectives:</b>
|
|
<ul><li class="half_rhythm"><div>Select patients who may benefit from sclerotherapy based on their clinical presentation.</div></li><li class="half_rhythm"><div>Select the sclerosant most likely to provide an optimal outcome for a patient based on their therapeutic goals.</div></li><li class="half_rhythm"><div>Identify and effectively treat the common complications of injection sclerotherapy for venous varicosities.</div></li><li class="half_rhythm"><div>Develop and implement effective interprofessional team strategies to improve outcomes for patients undergoing injection sclerotherapy.</div></li></ul>
|
|
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=145193&utm_source=pubmed&utm_campaign=reviews&utm_content=145193" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
|
</p></div><div id="article-145193.s2"><h2 id="_article-145193_s2_">Introduction</h2><p>Sclerotherapy is a group of techniques characterized by the injection of an irritating substance into a blood vessel to damage the vessel endothelium, induce inflammation with subsequent endofibrosis, and destroy the vessel.<a class="bibr" href="#article-145193.r1" rid="article-145193.r1">[1]</a><a class="bibr" href="#article-145193.r2" rid="article-145193.r2">[2]</a><a class="bibr" href="#article-145193.r3" rid="article-145193.r3">[3]</a> The irritating substances are termed sclerosing agents and include osmotic agents such as glycerin and hypertonic saline, detergents like polidocanol and sodium tetradecyl sulfate (STS), and iodinated substances.<a class="bibr" href="#article-145193.r2" rid="article-145193.r2">[2]</a><a class="bibr" href="#article-145193.r4" rid="article-145193.r4">[4]</a> Sclerotherapy is most commonly a primary or adjunctive therapy for cosmetically distressing or symptomatic venous varicosities of the lower extremities, but it also may be employed when treating certain hemorrhoids.<a class="bibr" href="#article-145193.r5" rid="article-145193.r5">[5]</a> Sclerotherapy remains the gold standard therapeutic intervention for lower extremity superficial varicose veins, reticular veins, and telangiectasia. </p><p>The treatment of venous insufficiency and varicosities dates back to Galen, Celsus, and Hippocrates.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> However, the modern medical references to sclerotherapy appeared in the 1850s. High infection rates secondary to treatments with perchloride of iron of mercury at that time resulted in the abandonment of sclerosing interventions until the early 1900s with the introduction of hypertonic saline as a sclerosing agent.<a class="bibr" href="#article-145193.r7" rid="article-145193.r7">[7]</a> Reiner introduced STS as a sclerosing agent in the 1940s, and the modern era of sclerotherapy was born.<a class="bibr" href="#article-145193.r7" rid="article-145193.r7">[7]</a></p></div><div id="article-145193.s3"><h2 id="_article-145193_s3_">Anatomy and Physiology</h2><p>Venous varicosities of the lower extremities are large, tortuous veins frequently visible beneath the skin, giving the extremities a lumpy, irregular contour and causing itching, pain, swelling, a feeling of heaviness, and occasionally bleeding.<a class="bibr" href="#article-145193.r1" rid="article-145193.r1">[1]</a> Venous varicosities affect nearly one-third of the population, of which 60% are women.<a class="bibr" href="#article-145193.r8" rid="article-145193.r8">[8]</a><a class="bibr" href="#article-145193.r9" rid="article-145193.r9">[9]</a>  The incidence of venous varicosities increases with age.<a class="bibr" href="#article-145193.r10" rid="article-145193.r10">[10]</a></p><p>Venous varicosities are often related to venous insufficiency of the deep or superficial venous systems or their connecting perforating vessels.<a class="bibr" href="#article-145193.r10" rid="article-145193.r10">[10]</a> Incompetence of the superficial venous system leads to visible varicosities, while deep venous insufficiency can cause lower extremity edema with subsequent hyperpigmentation, induration, and ulceration of the skin.<a class="bibr" href="#article-145193.r10" rid="article-145193.r10">[10]</a></p><p>Family history is the most significant predisposing factor for developing venous varicosities. However, activities or conditions that increase intraabdominal pressure and impede venous blood flow toward the heart, such as obesity, constipation, pregnancy, standing for long periods, and estrogen and progesterone supplementation, promote venous dilatation.<a class="bibr" href="#article-145193.r10" rid="article-145193.r10">[10]</a> Trauma may damage perforating veins and increase blood flow from the deep to the superficial circulatory system, promoting varicosity formation. Telangiectasias may occur secondary to localized trauma or in response to sun exposure or radiation damage.<a class="bibr" href="#article-145193.r10" rid="article-145193.r10">[10]</a> </p><p>Approximately 90% of the venous drainage in the lower extremities is via the deep venous system; incompetence of this system is usually due to insufficient venous valves that permit inappropriate backflow, increasing pressure on the superficial system and predisposing to superficial varicosities.<a class="bibr" href="#article-145193.r10" rid="article-145193.r10">[10]</a> Superficial venous varicosities contain increased collagen and decreased elastin, resulting in weakness of the vein wall and valves. Increased pressure from incompetent deep veins, especially when standing or walking, causes superficial venous distension.<a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a> </p><p>Venous varicosities are tortuous veins that measure greater than 4 to 5 mm in diameter; reticular veins measure from 1 to 4 mm in diameter. Telangiectasias are bluish vessels frequently found branching off reticular veins in fan-shaped arrays; they may be greater than 1 mm in diameter. Spider veins are reddish in color and measure less than 1 mm in diameter. <a class="bibr" href="#article-145193.r3" rid="article-145193.r3">[3]</a><a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> </p><p>Telangiectatic and venous varicosities are signs of venous insufficiency, a process characterized by the reversal of venous blood flow, which predisposes to the development of venous hypertension, an increase in venous diameter, and resultant valvular insufficiency. Incompetent communicating veins cause blood to flow back toward the deep venous system, increasing pressure and inducing dilatation of the superficial veins to accommodate this increased blood flow. The naturally occurring elevation in venous pressure inside the calf-muscle pump during movement of the lower limbs is transmitted directly to the superficial veins and subcutaneous tissues connected with these communicating veins. Telangiectasias also result from increased venous pressure in the superficial vascular system <a class="bibr" href="#article-145193.r10" rid="article-145193.r10">[10]</a>.</p><p>Treating telangiectasias, reticular veins, and venous varicosities requires a multifaceted approach involving medical therapies, lifestyle modifications such as exercise to improve the muscular pumps within the legs, weight loss to decrease central venous pressure, limb elevation, and compression garments which can be knee-high, thigh-high, or full-body.<a class="bibr" href="#article-145193.r8" rid="article-145193.r8">[8]</a> The classification of venous insufficiency comprises clinical, etiologic, anatomic, and pathologic features (CEAP), as shown in <b>Table 1.</b> Invasive treatment is indicated in C2 disease or greater, with surgical options including vein stripping or ligation, endovascular options such as ablation with radiofrequency devices, thermal or steam damage, or nonsurgical treatments such as sclerotherapy.<a class="bibr" href="#article-145193.r8" rid="article-145193.r8">[8]</a></p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figarticle145193table0"><a href="/books/NBK599526/table/article-145193.table0/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobarticle145193table0"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="article-145193.table0"><a href="/books/NBK599526/table/article-145193.table0/?report=objectonly" target="object" rid-ob="figobarticle145193table0">Table</a></h4><p class="float-caption no_bottom_margin">Table 1. CEAP Classification. </p></div></div><p>
|
|
<b>Sclerosants</b>
|
|
</p><p>The sclerosants commonly employed in current clinical practice can be classified as irritants, osmotic agents, or detergents.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a><a class="bibr" href="#article-145193.r12" rid="article-145193.r12">[12]</a> Sclerosants damage the endothelial cells of the tunica intima and the luminal 300 μm of the tunica media.<a class="bibr" href="#article-145193.r1" rid="article-145193.r1">[1]</a> Irritants and osmotic sclerosants are directly cytotoxic; detergents are less cytotoxic but disrupt intercellular connections.<a class="bibr" href="#article-145193.r1" rid="article-145193.r1">[1]</a> In the United States, the most commonly employed sclerosants are the osmotic agent hypertonic saline and the detergents STS and polidocanol.<a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a></p><p>Foam sclerosants were first described in the 1930s when air was incorporated into a vial of liquid detergent sclerosant via agitation to create a microfoam.<a class="bibr" href="#article-145193.r7" rid="article-145193.r7">[7]</a> This technique has undergone multiple modifications; the current technique of employing 2 syringes and a multiway stopcock was first described in 1997 by Tesari and Frullini.<a class="bibr" href="#article-145193.r7" rid="article-145193.r7">[7]</a> Foam sclerotherapy is favored over pure liquid sclerotherapy because foam bubbles increase the surface area of the liquid, prolonging contact with the vessel endothelium while minimizing the mixing of the sclerosant in the blood.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a><a class="bibr" href="#article-145193.r13" rid="article-145193.r13">[13]</a> Foam is more viscous, has an exponentially larger surface area, and allows for treatment to occur with a smaller volume while simultaneously increasing the length of efficacy within the target vein.<a class="bibr" href="#article-145193.r2" rid="article-145193.r2">[2]</a><a class="bibr" href="#article-145193.r14" rid="article-145193.r14">[14]</a> Foam induces a vasospastic response that apposes vessel walls and increases the likelihood that the vein remains obliterated.<a class="bibr" href="#article-145193.r2" rid="article-145193.r2">[2]</a> </p><p>The majority of sclerotherapy procedures are performed using room air; pure CO<sub>2</sub> and 70/30 mixtures of CO<sub>2</sub>/O<sub>2</sub> may be utilized. A ratio of 1-part liquid to 4- or 5-part gas is the most stable.<a class="bibr" href="#article-145193.r15" rid="article-145193.r15">[15]</a> Carbon dioxide offers several benefits over room air: it forms smaller bubbles and dissipates more quickly, increasing the surface area of endothelial contact and subsequent fibrosis, while dissolving more readily into the blood and decreasing adverse effects.<a class="bibr" href="#article-145193.r13" rid="article-145193.r13">[13]</a></p><p>
|
|
<b>Irritant Sclerosants</b>
|
|
</p><p>Irritants are corrosive agents that destroy cellular membranes and lead to vessel fibrosis.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> Typical irritants are ethanol, phenol, and polyiodinated iodine; polyiodinated iodines cause full-thickness vessel destruction. The historically but no longer utilized agents, perchloride of iron or mercury, are also irritants.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a></p><p>
|
|
<b>Osmotic Sclerosants</b>
|
|
</p><p>Osmotic sclerosants destroy cells by promoting rapid diffusion of intracellular fluid into the vessel, resulting in cellular dehydration and membrane disruption.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> The most commonly utilized osmotic sclerosants are 23% hypertonic saline (HTS) and glycerin.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a><a class="bibr" href="#article-145193.r16" rid="article-145193.r16">[16]</a></p><p>Hypertonic saline is an osmotic agent most commonly utilized when treating hyponatremia and cerebral edema. HTS is available in 3% or 23% concentrations; 23% HTS is used when treating varicose veins. The use of 23% HTS initially fell out of favor due to its adverse effect of extravasation necrosis, but its use was revived in the 1970s with the advent of fine-gauge, disposable syringes.<a class="bibr" href="#article-145193.r17" rid="article-145193.r17">[17]</a> This osmotic agent uses the concentration gradient between the endothelial cell and the intravascular space to cause fibrosis by denaturing the endothelial cell membrane. However, HTS is easily diluted in blood, rendering it ineffective unless a sufficient solution is injected to displace blood from the treated vein.<a class="bibr" href="#article-145193.r17" rid="article-145193.r17">[17]</a> HTS has a low toxicity profile and poses virtually no risk of anaphylaxis. However, the injection of HTS can cause localized transient pain, muscle cramping, or hyperpigmentation.<a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a></p><p>Glycerin (glycerol; 1,2,3-propanetriol) is a potent osmotic agent most frequently utilized to treat intracranial hypertension.<a class="bibr" href="#article-145193.r16" rid="article-145193.r16">[16]</a> The sclerosing effects of glycerol were first elucidated in 1925 by Jausion et al; glycerin induces mild endosclerosis within 45 minutes of administration.<a class="bibr" href="#article-145193.r16" rid="article-145193.r16">[16]</a> </p><p>
|
|
<b>Detergent Sclerosants</b>
|
|
</p><p>Detergent sclerosants disrupt cell membranes via protein denaturation.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> Detergent sclerosants also form micelles at certain concentrations and will form a foam when mixed with gas. Unlike other sclerosants, detergents in liquid and foam configurations cause endothelial damage within several minutes after administration; cellular injury can spread away from the injection site.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> Detergent sclerosants employed during sclerotherapy include STS, polidocanol, morrhuate sodium, and ethanolamine oleate. </p><p>STS is a small, synthetic organic sodium salt; 2% benzyl alcohol is added to the formulation for anesthetic purposes in medical use.<a class="bibr" href="#article-145193.r12" rid="article-145193.r12">[12]</a> STS is a clear, nonviscous solution that evenly distributes within the blood following injection and rapidly clears as it attaches to red blood cells and causes hemolysis <a class="bibr" href="#article-145193.r12" rid="article-145193.r12">[12]</a>.  </p><p>Polidocanol is a synthetic polyethylene glycol initially marketed as a local anesthetic.<a class="bibr" href="#article-145193.r7" rid="article-145193.r7">[7]</a> However, injection of polidocanol was found to cause venous sclerosis. While it is still used as a topical anesthetic, its primary use is as a sclerosant.<a class="bibr" href="#article-145193.r18" rid="article-145193.r18">[18]</a> Polidocanol for sclerotherapy is dissolved in distilled water and ethanol to achieve a 5% concentration that facilitates micelle formation.<a class="bibr" href="#article-145193.r12" rid="article-145193.r12">[12]</a></p><p>Polidocanol and STS come in various concentrations, each with recommendations for the size of the vein that can be treated (see <b>Table 2.</b> Size Requirements for STS and Polidocanol Based on Concentration). The incidence of allergic or anaphylactic reaction following STS or polidocanol injection is less than 1%.<a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a>The 3% STS foam is more potent than 3% Polidocanol, rendering 3% STS foam more appropriate for use on larger veins. Polidocanol is more appropriate for telangiectasias or reticular veins due to its anesthetic properties and decreased risk of thrombophlebitis.<a class="bibr" href="#article-145193.r19" rid="article-145193.r19">[19]</a></p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figarticle145193table1"><a href="/books/NBK599526/table/article-145193.table1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobarticle145193table1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="article-145193.table1"><a href="/books/NBK599526/table/article-145193.table1/?report=objectonly" target="object" rid-ob="figobarticle145193table1">Table</a></h4><p class="float-caption no_bottom_margin">Table 2. Size requirements for STS and Polidocanol based on concentration. </p></div></div></div><div id="article-145193.s4"><h2 id="_article-145193_s4_">Indications</h2><p>Sclerotherapy techniques are indicated in the treatment of venous varicosities and certain hemorrhoids. The sclerosants utilized in these therapeutic interventions vary.</p><p>Liquid or foam sclerotherapy is an indicated treatment for cosmetically distressing or disturbing varicose veins, spider veins, reticular veins, and telangiectasias. These therapies are also employed when treating saphenous vein reflux, enlarged tributary and perforator veins, and vascular malformations.<a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a> Sclerotherapy can also be used to treat smaller collateral veins not amenable to stab phlebectomy or ablation.</p><p>A meta-analysis of foam sclerotherapy as a treatment for venous ulceration or C5-C6 venous insufficiency revealed that foam sclerotherapy may be superior to compression therapy alone. However, this meta-analysis evaluated a few markedly heterogeneous studies; more research is needed.<a class="bibr" href="#article-145193.r20" rid="article-145193.r20">[20]</a></p><p>Utilizing ultrasound guidance during sclerotherapy for venous insufficiency provides a simple, efficacious, targeted method to treat deep venous insufficiency.<a class="bibr" href="#article-145193.r21" rid="article-145193.r21">[21]</a> Studies have reported extremely high satisfaction rates with ultrasound-guided sclerotherapy (UGS); one study reported that 100% of patients were satisfied with the degree of treatment, and more than 90% reported improved quality of life and appearance of the treated limb.[19] Ultrasound-guided sclerotherapy may be appropriate for any patient but is particularly useful when treating patients with obesity, insufficiency of the great saphenous vein, and whose comorbidities preclude more invasive surgery.<a class="bibr" href="#article-145193.r13" rid="article-145193.r13">[13]</a><a class="bibr" href="#article-145193.r21" rid="article-145193.r21">[21]</a><a class="bibr" href="#article-145193.r22" rid="article-145193.r22">[22]</a></p><p>Sclerotherapy is also indicated when treating patients with symptomatic hemorrhoids, active bleeding, risks of major bleeding, and those with HIV or AIDS. Phenol in almond oil and 3% polidocanol are the sclerosants recommended for treating grades 1 through 3 hemorrhoids; aluminum potassium sulfate and tannic acid (ALTA)are recommended for treating grades 2 through 4 hemorrhoids.<a class="bibr" href="#article-145193.r5" rid="article-145193.r5">[5]</a></p></div><div id="article-145193.s5"><h2 id="_article-145193_s5_">Contraindications</h2><p>There are several absolute and relative contraindications to sclerotherapy for venous varicosities; in patients for whom sclerotherapy is contraindicated, other treatment options, such as stab phlebectomy, should be considered.<a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a> The contraindications for patients with venous varicosities differ from those with hemorrhoids.</p><p>Absolute contraindications to sclerotherapy for the treatment of venous varicosities include but are not limited to specific sclerosant allergy, current systemic infection or that localized to the treatment area, and a personal history of deep venous thrombosis, severe peripheral arterial disease, advanced collagen vascular diseases, or cardiovascular or neurologic events following sclerosant injection.<a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a><a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a><a class="bibr" href="#article-145193.r23" rid="article-145193.r23">[23]</a></p><p>Relative contraindications to sclerotherapy for the treatment of venous varicosities include severely impaired mobility and a personal history of a marked allergic diathesis, asthma, severe deep venous incompetence, or thrombophilia. Sclerotherapy may also be relatively contraindicated in patients who are currently pregnant or breastfeeding.<a class="bibr" href="#article-145193.r19" rid="article-145193.r19">[19]</a><a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a> Visual disturbances and transient ischemic attacks, possibly due to paradoxical emboli, have been reported following foam sclerotherapy in patients with a patent foramen ovale.<a class="bibr" href="#article-145193.r1" rid="article-145193.r1">[1]</a><a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a> Large varices may be a relative contraindication to sclerotherapy due to the increased risk of recanalization.</p><p>Contraindications to the use of sclerotherapy in the treatment of hemorrhoids include thrombosed hemorrhoids and a personal history of asthma, specific sclerosant allergy, thrombophilia, inflammatory bowel disease, and cardiac, renal, or hepatic comorbidities.<a class="bibr" href="#article-145193.r5" rid="article-145193.r5">[5]</a></p></div><div id="article-145193.s6"><h2 id="_article-145193_s6_">Equipment</h2><p>The equipment required to perform sclerotherapy typically includes:</p><ul><li class="half_rhythm"><div>Needle, 30-gauge or smaller</div></li><li class="half_rhythm"><div>Multiple 5-mL syringes</div></li><li class="half_rhythm"><div>Sclerosant of choice</div></li><li class="half_rhythm"><div>Local anesthetic</div></li><li class="half_rhythm"><div>Gauze dressings</div></li><li class="half_rhythm"><div>Compressive bandages</div></li><li class="half_rhythm"><div>Ultrasound (if performing ultrasound-guided sclerotherapy)</div></li></ul></div><div id="article-145193.s7"><h2 id="_article-145193_s7_">Personnel</h2><p>The personnel required to perform sclerotherapy in an office-based setting typically include:</p><ul><li class="half_rhythm"><div>Primary clinician trained in sclerotherapy</div></li><li class="half_rhythm"><div>Assistant</div></li></ul><p>The personnel required to perform sclerotherapy in a hospital-based setting, perhaps as part of a more complex procedure, typically include:</p><ul><li class="half_rhythm"><div>Primary clinician trained in sclerotherapy</div></li><li class="half_rhythm"><div>Surgical technician or operating room nurse</div></li><li class="half_rhythm"><div>Circulating or operating room nurse</div></li><li class="half_rhythm"><div>Anesthesia personnel</div></li></ul></div><div id="article-145193.s8"><h2 id="_article-145193_s8_">Preparation</h2><p>The patient and primary clinician should engage in shared decision-making before the procedure to ensure an understanding of the possibility of adverse events and the risk of cosmetic complications such as hyperpigmentation and telangiectatic matting. These risks are increased in patients taking combined oral contraceptives, disulfiram, or minocycline.<a class="bibr" href="#article-145193.r23" rid="article-145193.r23">[23]</a></p><p>Sclerotherapy is typically performed with the patient in the supine or seated position, as dictated by optimum visualization of the target vessels. The identified procedural areas should be prepped and draped in a sterile fashion. If ultrasound guidance is employed, the machine should be set to vascular mode. Detergent sclerosants to be used as foam should be combined with air employing the Tessari or double-syringe technique (see <b>Figure.</b> Schematic of Tessari Technique).<a class="bibr" href="#article-145193.r24" rid="article-145193.r24">[24]</a><a class="bibr" href="#article-145193.r15" rid="article-145193.r15">[15]</a></p></div><div id="article-145193.s9"><h2 id="_article-145193_s9_">Technique or Treatment</h2><p>Sclerosant injection should be carried out in a “downstream” fashion from the largest to the smallest vessels, such that the sclerosant will flow from the injection site into other target veins.<a class="bibr" href="#article-145193.r3" rid="article-145193.r3">[3]</a><a class="bibr" href="#article-145193.r17" rid="article-145193.r17">[17]</a> The entire superficial venous system of each leg should be treated in one setting to avoid recanalization or hyperpigmentation due to the extravasation of erythrocytes from the damaged vessel.</p><p>Cannulate the target vein with a 30-gauge or smaller needle; confirm correct intravascular placement using aspiration.<a class="bibr" href="#article-145193.r2" rid="article-145193.r2">[2]</a><a class="bibr" href="#article-145193.r17" rid="article-145193.r17">[17]</a> Once intravascular placement is confirmed, inject only enough sclerosant to displace the blood from the vessel.<a class="bibr" href="#article-145193.r3" rid="article-145193.r3">[3]</a> For reticular veins, spider veins, and telangiectasias, inject only enough sclerosant to induce blanching of the system; blanching confirms successful treatment.<a class="bibr" href="#article-145193.r17" rid="article-145193.r17">[17]</a> Using the lowest necessary volume and concentration for vessel injection reduces the risk of initiating new telangiectasias around the treated area. </p><p>Patients should remain supine or seated for several minutes following sclerosant injection. The treated extremity should be wrapped with a compressive dressing, or compression stockings should be worn. Dressings and stocking should not be removed for 7 days to promote compression of the treated vessels. Applying compression immediately following sclerotherapy minimizes thrombus formation. Patients should be encouraged to ambulate with the compressive wraps or garments in place.</p></div><div id="article-145193.s10"><h2 id="_article-145193_s10_">Complications</h2><p>Localized adverse effects of sclerotherapy for venous varicosities include but are not limited to pain with or following sclerosant injection, erythema, edema, pruritus, ulceration, increased hair growth, and telangiectatic matting characterized by the appearance of a complex of fine, red veins in the treated area.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a><a class="bibr" href="#article-145193.r13" rid="article-145193.r13">[13]</a> Pain during sclerosant injection is especially common with HTS and glycerin.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> Approximately 30% of patients may experience skin hyperpigmentation or discoloration from hemosiderin deposition 6 to 8 weeks following sclerotherapy.<a class="bibr" href="#article-145193.r11" rid="article-145193.r11">[11]</a> A systematic review of patients who underwent sclerotherapy with polidocanol demonstrated that hyperpigmentation was more common with a higher sclerosant concentration or treatment focused on superficial venous systems such as the epifascial vessels.<a class="bibr" href="#article-145193.r25" rid="article-145193.r25">[25]</a></p><p>Systemic adverse effects of sclerotherapy include chest tightness, visual disturbances, transient ischemic attacks, dizziness, and migraine headaches; headaches are more likely to occur in patients with a history of migrainous events.<a class="bibr" href="#article-145193.r13" rid="article-145193.r13">[13]</a> These adverse effects occur more frequently following unintentional injection of the deep venous system and ultrasound-guided treatment of the great saphenous vein.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a><a class="bibr" href="#article-145193.r13" rid="article-145193.r13">[13]</a></p><p>The incomplete destruction of the target vessel may lead to recanalization and the need for additional procedures; prolonged compression of the treated limb assists healing and minimizes the risk of recanalization.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> A systematic review noted no significant differences in the rate of complications or optimal outcomes between foam and liquid sclerotherapy.<a class="bibr" href="#article-145193.r1" rid="article-145193.r1">[1]</a></p><p>The osmotic agents HTS and glycerin carry an increased risk for local tissue damage and ulceration if the solution extravasates or is injected into an arteriole.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> Intraarterial injection of HTS or glycerin can potentially induce acute limb ischemia that requires amputation.<a class="bibr" href="#article-145193.r26" rid="article-145193.r26">[26]</a> Additionally, glycerin may cause mild hematuria; adding a chromated alum to the glycerol molecule can mitigate this adverse effect. This modification increases the potency of the sclerosant.<a class="bibr" href="#article-145193.r16" rid="article-145193.r16">[16]</a></p><p>The most common complication of hemorrhoid sclerotherapy is an easily treatable localized infection; more severe infections and sepsis have been reported. Additionally, improper or excessive sclerosant injection may lead to surrounding tissue necrosis and complications such as rectovaginal fistulae.<a class="bibr" href="#article-145193.r5" rid="article-145193.r5">[5]</a></p></div><div id="article-145193.s11"><h2 id="_article-145193_s11_">Clinical Significance</h2><p>Sclerotherapy is a clinically significant treatment modality for venous varicosities, offering a minimally invasive approach with substantial therapeutic benefits via a controlled thrombophelbitic reaction. Sclerotherapy is effective in treating varicose veins, spider veins, and telangiectasia in a short amount of time. Injection sclerotherapy provides notable cosmetic improvement by reducing the appearance of unsightly veins and enhancing patients' confidence and quality of life. Moreover, injection sclerotherapy alleviates symptoms associated with venous insufficiency, such as pain, swelling, and discomfort, leading to improved overall vascular health.</p><p>Injection sclerotherapy is versatile, offers primary or adjunctive therapeutic options, is applicable in various settings, and can be performed on an outpatient basis without the need for extensive recovery time. Its minimally invasive nature makes it an attractive option for patients averse to surgery or for whom surgery is contraindicated. Furthermore, advancements in sclerosing agents and techniques have enhanced efficacy and safety, contributing to the widespread use of injection sclerotherapy in managing venous varicosities.</p><p>Overall, sclerotherapy offers cosmetic enhancement and symptomatic relief, making it an inherently valuable treatment option for patients with venous disease.</p></div><div id="article-145193.s12"><h2 id="_article-145193_s12_">Enhancing Healthcare Team Outcomes </h2><p>Patients with venous varicosities often require multimodality treatments ranging from compression therapy to surgical intervention to achieve optimal results.<a class="bibr" href="#article-145193.r6" rid="article-145193.r6">[6]</a> Asymptomatic patients may wish only to improve cosmesis; symptomatic patients may additionally desire symptom relief. Patients with venous varicosities frequently present to various healthcare providers, including primary care providers, plastic surgeons, dermatologists, or vascular surgeons. If the venous disease has resulted in ulceration, wound care specialists may be involved. A comprehensive understanding of the multimodal therapies employed in venous varicosity treatment is needed to provide optimal patient care.</p><p>The Cochrane database reviews several available interventions for treating venous varicosities, including laser or radiofrequency endovenous ablation therapy, ultrasound-guided foam sclerotherapy, and traditional surgery. Low-to-moderate–quality evidence suggests that 1-year recanalization rates are lower following endovenous ablation therapy than conventional surgery. However, the review could not determine whether ultrasound-guided foam sclerotherapy was superior to traditional surgery.<a class="bibr" href="#article-145193.r27" rid="article-145193.r27">[27]</a> </p><p>Achieving optimal outcomes following injection sclerotherapy necessitates a collaborative interprofessional approach that engages in shared decision-making with patients, ensuring alignment with individual preferences, understanding potential risks, and establishing realistic treatment expectations. Effective communication among team members and patients enhances treatment efficacy and patient satisfaction. Clinical staff, including nurses, assistants, and pharmacists, play a critical role in patient education, providing preprocedural guidance and postprocedural care instructions.</p><p>An interprofessional approach and shared decision-making ultimately foster patient-centered care, optimizing injection sclerotherapy outcomes. This approach ensures comprehensive evaluation, personalized treatment strategies, and patient empowerment, enhancing treatment adherence, improved outcomes, and overall patient satisfaction.</p></div><div id="article-145193.s13"><h2 id="_article-145193_s13_">Review Questions</h2><ul><li class="half_rhythm"><div>
|
|
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=145193&utm_source=pubmed&utm_campaign=reviews&utm_content=145193" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<a href="https://mdsearchlight.com/therapeutics/sclerotherapy-varicose-vein-treatment/?utm_source=pubmedlink&utm_campaign=MDS&utm_content=145193" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Click here for a simplified version.</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<a href="https://www.statpearls.com/articlelibrary/commentarticle/145193/?utm_source=pubmed&utm_campaign=comments&utm_content=145193" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Comment on this article.</a>
|
|
</div></li></ul></div><div class="floats-group" id="article-145193.s14"><div class="iconblock whole_rhythm clearfix ten_col fig" id="figarticle145193imagef1" co-legend-rid="figlgndarticle145193imagef1"><a href="/books/NBK599526/figure/article-145193.image.f1/?report=objectonly" target="object" title="Figure" class="img_link icnblk_img figpopup" rid-figpopup="figarticle145193imagef1" rid-ob="figobarticle145193imagef1"><img class="small-thumb" src="/books/NBK599526/bin/Screen__Shot__2023-09-08__at__3.13.46__PM.gif" src-large="/books/NBK599526/bin/Screen__Shot__2023-09-08__at__3.13.46__PM.jpg" alt="Schematic of Tessari Technique UpToDate https://ykhoa" /></a><div class="icnblk_cntnt" id="figlgndarticle145193imagef1"><h4 id="article-145193.image.f1"><a href="/books/NBK599526/figure/article-145193.image.f1/?report=objectonly" target="object" rid-ob="figobarticle145193imagef1">Figure</a></h4><p class="float-caption no_bottom_margin">Schematic of Tessari Technique UpToDate https://ykhoa.org/d/image.htm?imageKey=SURG/79497 </p></div></div></div><div id="article-145193.s15"><h2 id="_article-145193_s15_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="article-145193.r1">de Ávila Oliveira R, Riera R, Vasconcelos V, Baptista-Silva JC. Injection sclerotherapy for varicose veins. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2021 Dec 10;<span class="ref-vol">12</span>(12):CD001732.</span> [<a href="/pmc/articles/PMC8660237/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8660237</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34883526" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34883526</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="article-145193.r2">Palm MD, Guiha IC, Goldman MP. Foam sclerotherapy for reticular veins and nontruncal varicose veins of the legs: a retrospective review of outcomes and adverse effects. <span><span class="ref-journal">Dermatol Surg. </span>2010 Jun;<span class="ref-vol">36 Suppl 2</span>:1026-33.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20590709" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20590709</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="article-145193.r3">Goldman MP. My sclerotherapy technique for telangiectasia and reticular veins. <span><span class="ref-journal">Dermatol Surg. </span>2010 Jun;<span class="ref-vol">36 Suppl 2</span>:1040-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20590711" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20590711</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="article-145193.r4">Weiss MA, Hsu JT, Neuhaus I, Sadick NS, Duffy DM. Consensus for sclerotherapy. <span><span class="ref-journal">Dermatol Surg. </span>2014 Dec;<span class="ref-vol">40</span>(12):1309-18.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25418805" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25418805</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="article-145193.r5">He A, Chen M. Sclerotherapy in Hemorrhoids. <span><span class="ref-journal">Indian J Surg. </span>2023 Apr;<span class="ref-vol">85</span>(2):228-232.</span> [<a href="/pmc/articles/PMC9022405/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9022405</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35469212" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35469212</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="article-145193.r6">Worthington-Kirsch RL. Injection sclerotherapy. <span><span class="ref-journal">Semin Intervent Radiol. </span>2005 Sep;<span class="ref-vol">22</span>(3):209-17.</span> [<a href="/pmc/articles/PMC3036277/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3036277</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21326695" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21326695</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="article-145193.r7">Myers K. A history of injection treatments - II sclerotherapy. <span><span class="ref-journal">Phlebology. </span>2019 Jun;<span class="ref-vol">34</span>(5):303-310.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30336757" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30336757</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="article-145193.r8">Chwała M, Szczeklik W, Szczeklik M, Aleksiejew-Kleszczyński T, Jagielska-Chwała M. Varicose veins of lower extremities, hemodynamics and treatment methods. <span><span class="ref-journal">Adv Clin Exp Med. </span>2015 Jan-Feb;<span class="ref-vol">24</span>(1):5-14.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25923081" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25923081</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="article-145193.r9">Lorenz MB, Gkogkolou P, Goerge T. Sclerotherapy of varicose veins in dermatology. <span><span class="ref-journal">J Dtsch Dermatol Ges. </span>2014 May;<span class="ref-vol">12</span>(5):391-3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24797742" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24797742</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="article-145193.r10">Goldman MP, Weiss RA, Bergan JJ. Diagnosis and treatment of varicose veins: a review. <span><span class="ref-journal">J Am Acad Dermatol. </span>1994 Sep;<span class="ref-vol">31</span>(3 Pt 1):393-413; quiz 414-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8077464" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8077464</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="article-145193.r11">Andrews RH, Dixon RG. Ambulatory Phlebectomy and Sclerotherapy as Tools for the Treatment of Varicose Veins and Telangiectasias. <span><span class="ref-journal">Semin Intervent Radiol. </span>2021 Jun;<span class="ref-vol">38</span>(2):160-166.</span> [<a href="/pmc/articles/PMC8175112/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8175112</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34108801" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34108801</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="article-145193.r12">Rao J, Wildemore JK, Goldman MP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. <span><span class="ref-journal">Dermatol Surg. </span>2005 Jun;<span class="ref-vol">31</span>(6):631-5; discussion 635.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15996411" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15996411</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="article-145193.r13">Peterson JD, Goldman MP. An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. <span><span class="ref-journal">Phlebology. </span>2012 Mar;<span class="ref-vol">27</span>(2):73-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21926097" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21926097</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="article-145193.r14">Tremaine AM, Friedmann DP, Goldman MP. Foam sclerotherapy for reticular veins of the dorsal hands: a retrospective review. <span><span class="ref-journal">Dermatol Surg. </span>2014 Aug;<span class="ref-vol">40</span>(8):892-8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25022711" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25022711</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="article-145193.r15">Peterson JD, Goldman MP. An investigation into the influence of various gases and concentrations of sclerosants on foam stability. <span><span class="ref-journal">Dermatol Surg. </span>2011 Jan;<span class="ref-vol">37</span>(1):12-7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21199095" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21199095</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="article-145193.r16">Leach BC, Goldman MP. Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. <span><span class="ref-journal">Dermatol Surg. </span>2003 Jun;<span class="ref-vol">29</span>(6):612-4; discussion 615.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12786704" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12786704</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="article-145193.r17">McCoy S, Evans A, Spurrier N. Sclerotherapy for leg telangiectasia--a blinded comparative trial of polidocanol and hypertonic saline. <span><span class="ref-journal">Dermatol Surg. </span>1999 May;<span class="ref-vol">25</span>(5):381-5; discussion 385-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10469077" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10469077</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="article-145193.r18">Duffy DM. Sclerosants: a comparative review. <span><span class="ref-journal">Dermatol Surg. </span>2010 Jun;<span class="ref-vol">36 Suppl 2</span>:1010-25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20590708" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20590708</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="article-145193.r19">Barrett JM, Allen B, Ockelford A, Goldman MP. Microfoam ultrasound-guided sclerotherapy of varicose veins in 100 legs. <span><span class="ref-journal">Dermatol Surg. </span>2004 Jan;<span class="ref-vol">30</span>(1):6-12.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14692919" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14692919</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="article-145193.r20">Joyce DP, De Freitas S, Woo EY, Tang TY, Tubassam M, Walsh SR. Ultrasound-guided foam sclerotherapy as a therapeutic modality in venous ulceration. <span><span class="ref-journal">Surgeon. </span>2022 Oct;<span class="ref-vol">20</span>(5):e206-e213.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34629303" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34629303</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="article-145193.r21">Barrett JM, Allen B, Ockelford A, Goldman MP. Microfoam ultrasound-guided sclerotherapy treatment for varicose veins in a subgroup with diameters at the junction of 10 mm or greater compared with a subgroup of less than 10 mm. <span><span class="ref-journal">Dermatol Surg. </span>2004 Nov;<span class="ref-vol">30</span>(11):1386-90.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15522019" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15522019</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="article-145193.r22">Breu FX, Guggenbichler S, Wollmann JC., Second European Consensus Meeting on Foam Sclerotherapy. Duplex ultrasound and efficacy criteria in foam sclerotherapy from the 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. <span><span class="ref-journal">Vasa. </span>2008 Feb;<span class="ref-vol">37</span>(1):90-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18512547" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18512547</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="article-145193.r23">Wong M, Parsi K, Myers K, De Maeseneer M, Caprini J, Cavezzi A, Connor DE, Davies AH, Gianesini S, Gillet JL, Grondin L, Guex JJ, Hamel-Desnos C, Morrison N, Mosti G, Orrego A, Partsch H, Rabe E, Raymond-Martimbeau P, Schadeck M, Simkin R, Tessari L, Thibault PK, Ulloa JH, Whiteley M, Yamaki T, Zimmet S, Kang M, Vuong S, Yang A, Zhang L. Sclerotherapy of lower limb veins: Indications, contraindications and treatment strategies to prevent complications - A consensus document of the International Union of Phlebology-2023. <span><span class="ref-journal">Phlebology. </span>2023 May;<span class="ref-vol">38</span>(4):205-258.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36916540" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36916540</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="article-145193.r24">Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M, Michaels J. Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation. <span><span class="ref-journal">Health Technol Assess. </span>2013 Oct;<span class="ref-vol">17</span>(48):i-xvi, 1-141.</span> [<a href="/pmc/articles/PMC4780990/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4780990</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24176098" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24176098</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="article-145193.r25">Bossart S, Daneluzzi C, Cazzaniga S, Ramelet AA, Uthoff H, Seyed Jafari SM, Baumgartner M, Hunger RE, Heidemeyer K, Willenberg T. Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review. <span><span class="ref-journal">J Eur Acad Dermatol Venereol. </span>2023 Feb;<span class="ref-vol">37</span>(2):274-283.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36196455" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36196455</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="article-145193.r26">Yiannakopoulou E. Safety Concerns for Sclerotherapy of Telangiectases, Reticular and Varicose Veins. <span><span class="ref-journal">Pharmacology. </span>2016;<span class="ref-vol">98</span>(1-2):62-9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27104778" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27104778</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="article-145193.r27">Paravastu SC, Horne M, Dodd PD. Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2016 Nov 29;<span class="ref-vol">11</span>(11):CD010878.</span> [<a href="/pmc/articles/PMC6464398/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6464398</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27898181" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27898181</span></a>]</div></dd></dl></dl></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Amanda Beneat declares no relevant financial relationships with ineligible companies.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Alisha Oropallo declares no relevant financial relationships with ineligible companies.</p></div></dd></dl></dl></div></div></div><div class="fm-sec"><h2 id="_NBK599526_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Amanda Beneat</span><sup>1</sup>; <span itemprop="author">Alisha Oropallo</span><sup>2</sup>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> New York University</div><div class="affiliation"><sup>2</sup> Zucker Hofstra Medical School</div><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">January 11, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 2025, StatPearls Publishing LLC.<p class="small">
|
|
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
|
|
(<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">
|
|
http://creativecommons.org/licenses/by-nc-nd/4.0/
|
|
</a>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
|
|
</p></div></div><h3>Publisher</h3><p><a href="https://www.statpearls.com/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">StatPearls Publishing</a>, Treasure Island (FL)</p><h3>NLM Citation</h3><p>Beneat A, Oropallo A. Sclerotherapy. [Updated 2024 Jan 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobarticle145193table0"><div id="article-145193.table0" class="table"><h3><span class="title">Table 1. CEAP Classification</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK599526/table/article-145193.table0/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__article-145193.table0_lrgtbl__"><table style="width: 600px; border-color: black;" cellspacing="1" cellpadding="5" class="no_top_margin"><tbody><tr><td rowspan="1" colspan="1" style="width: 80px;vertical-align:top;">
|
|
<b>CEAP Classification</b>
|
|
</td><td rowspan="1" colspan="1" style="width: 377.128px;vertical-align:top;">
|
|
<b>Features</b>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="width: 80px;vertical-align:top;">C1</td><td rowspan="1" colspan="1" style="width: 377.128px;vertical-align:top;">Reticular veins, telangiectasias, or spider veins of purely cosmetic concern</td></tr><tr><td rowspan="1" colspan="1" style="width: 80px;vertical-align:top;">C2a</td><td rowspan="1" colspan="1" style="width: 377.128px;vertical-align:top;">Asymptomatic varicose veins </td></tr><tr><td rowspan="1" colspan="1" style="width: 80px;vertical-align:top;">C2b</td><td rowspan="1" colspan="1" style="width: 377.128px;vertical-align:top;">Symptomatic varicose veins (itching, pain, thrombosis, bleeding) </td></tr><tr><td rowspan="1" colspan="1" style="width: 80px;vertical-align:top;">C3</td><td rowspan="1" colspan="1" style="width: 377.128px;vertical-align:top;">Edema due to varicose veins </td></tr><tr><td rowspan="1" colspan="1" style="width: 80px;vertical-align:top;">C4</td><td rowspan="1" colspan="1" style="width: 377.128px;vertical-align:top;">Skin changes such as lipodermatosclerosis or hyperpigmentation</td></tr><tr><td rowspan="1" colspan="1" style="width: 80px;vertical-align:top;">C5</td><td rowspan="1" colspan="1" style="width: 377.128px;vertical-align:top;">Healed venous ulcers </td></tr><tr><td rowspan="1" colspan="1" style="width: 80px;vertical-align:top;">C6</td><td rowspan="1" colspan="1" style="width: 377.128px;vertical-align:top;">Active venous ulcers</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobarticle145193table1"><div id="article-145193.table1" class="table"><h3><span class="title">Table 2. Size requirements for STS and Polidocanol based on concentration.</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK599526/table/article-145193.table1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__article-145193.table1_lrgtbl__"><table style="width: 757px; border-color: black;" cellspacing="1" cellpadding="5" class="no_top_margin"><tbody><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">Concentration</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Vein type and diameter </td></tr><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">STS liquid 0.1%-0.3%</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Telangiectatic veins 0.2-1 mm</td></tr><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">STS liquid 0.5%-1%</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Uncomplicated varicose veins 2-4 mm</td></tr><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">STS foam 0.25%-1% (1:4 ratio)</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Large reticular and varicose veins 3-6 mm</td></tr><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">STS foam 3% (1:4 ratio)</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Great saphenous vein or veins up to 10 mm</td></tr><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">Polidocanol 0.5%</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Telangiectasias <1 mm</td></tr><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">Polidocanol 1%</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Veins 1-2 mm</td></tr><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">Polidocanol 2%</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Reticular and varicose veins 2-4 mm</td></tr><tr><td rowspan="1" colspan="1" style="width: 260.038px;vertical-align:top;">Polidocanol 3%</td><td rowspan="1" colspan="1" style="width: 488.962px;vertical-align:top;">Larger veins 4-8 mm</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobarticle145193imagef1"><div id="article-145193.image.f1" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK599526/bin/Screen__Shot__2023-09-08__at__3.13.46__PM.jpg" alt="Schematic of Tessari Technique UpToDate https://ykhoa" /></div><div class="caption"><p>Schematic of Tessari Technique UpToDate https://ykhoa.org/d/image.htm?imageKey=SURG/79497</p></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|